Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

Recruiting now

Conditions studied: Knee Osteoarthritis

In brief

As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.

Key facts

Study ID
NCT06357741
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
People needed
30
Starts
2021-08-01
Expected to finish
2025-12-31
Last updated by the study team
2025-04-09

Who can join

Age: 45 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.